Navigation Links
Techne Corporation Declares Dividend
Date:7/31/2012

MINNEAPOLIS, July 31, 2012 /PRNewswire/ -- Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.28 per share for the quarter ended June 30, 2012.  The quarterly dividend will be payable August 24, 2012 to all common shareholders of record on August 10, 2012.  Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Techne Corporation has two operating subsidiaries:  Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty manufacturer of biological products.  R&D Systems has three operating subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. Boston Biochem is a leading developer and manufacturer of ubiquitin-related research products. R&D China and R&D Europe distribute biotechnology products.  R&D Europe has two subsidiaries, Tocris Holding, Ltd (Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation.  Tocris is a leading supplier of reagents for non-clinical life science research.


'/>"/>
SOURCE Techne Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Neogen Corporation Announces 2nd Quarter Results Conference Call
5. Luminex Corporation to Present at JP Morgan Healthcare Conference
6. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
9. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
10. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
11. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017  Asterias Biotherapeutics, Inc. ... field of regenerative medicine, today announced positive efficacy ... clinical trial that showed additional motor function improvement ... million AST-OPC1 cells in AIS-A patients with complete ... of upper extremity motor function is critically important ...
(Date:1/24/2017)... Switerland (PRWEB) , ... January 24, 2017 , ... ... first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of histidine ... which are available in a range of concentrations from six different malaria strains, ...
(Date:1/24/2017)... , ... January 23, 2017 , ... Oklahoma City based ... newest client for the firm’s PERFEQTA software and legacy product QC Manager 2.0. ... the dynamic team at CJBC and thrilled that they have decided to implement PERFEQTA ...
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... into an underwriting agreement with Rodman & Renshaw, a ... as sole book running manager and representative of several underwriters, ... a firm commitment basis a minimum of 2,105,264 shares ... to purchase a minimum of 1,052,632 shares of common ...
Breaking Biology Technology:
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):